These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 1516794)

  • 41. Oligoclonal reconstitution masquerading as myeloma relapse.
    Chim CS; Chan EY
    Ann Hematol; 2013 Jun; 92(6):847-8. PubMed ID: 23150202
    [No Abstract]   [Full Text] [Related]  

  • 42. Phase II study of topotecan and cyclophosphamide in patients with relapsed and refractory multiple myeloma.
    Kraut EH; Young D; Farag S; James AG; Solove RJ
    Leuk Res; 2005 Oct; 29(10):1233-4. PubMed ID: 16111541
    [No Abstract]   [Full Text] [Related]  

  • 43. [Combination chemotherapy (modified M-2 protocol) for multiple myeloma].
    Iwata Y; Karitani Y; Tanaka I; Kobayashi T; Ohno T; Kageyama S; Katayama N; Kataoka Y; Kamio N; Ohota C
    Rinsho Ketsueki; 1984 Sep; 25(9):1380-7. PubMed ID: 6549187
    [No Abstract]   [Full Text] [Related]  

  • 44. [The clinical study on treatment with bortezomib for multiple myeloma].
    Chen C; Zhao CL; Hou M
    Zhonghua Xue Ye Xue Za Zhi; 2011 Apr; 32(4):265-7. PubMed ID: 21569711
    [No Abstract]   [Full Text] [Related]  

  • 45. Efficacy of thalidomide-based therapy following lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma.
    Kukreti V; Masih-Khan E; Young T; Chu CM; Jiang H; Trudel S; Chen C; Jimenez-Zepeda V; Reece DE
    Am J Hematol; 2013 Apr; 88(4):337-8. PubMed ID: 23494911
    [No Abstract]   [Full Text] [Related]  

  • 46. Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide- and lenalidomide-containing regimens.
    Storrar NPF; Mathur A; Johnson PRE; Roddie PH
    Br J Haematol; 2019 Apr; 185(1):142-144. PubMed ID: 29785771
    [No Abstract]   [Full Text] [Related]  

  • 47. [PAD regimen for relapsed or refractory patients with multiple myeloma].
    Zhang YQ; Liang R; Bai QX; Zhang T; Yang L; Wang YW; Wang WQ; Gu HT; Shu MM; Zhu HF; Bai YN; Chen XQ
    Zhonghua Xue Ye Xue Za Zhi; 2009 Apr; 30(4):260-3. PubMed ID: 19731828
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Salivary amylase-producing multiple myeloma: case report and review of the current literature.
    Sosnoff DR; Friend RB; Berkovic M; Rasansky RJ; Hoffman SM
    J Clin Oncol; 2013 Jul; 31(19):e309-11. PubMed ID: 23690421
    [No Abstract]   [Full Text] [Related]  

  • 49. [Polychemotherapy of multiple myeloma using pafencil (COPPaf protocol)].
    Tsykalov VA; Zhuravlev VS; Mokeeva RA
    Gematol Transfuziol; 1989 Apr; 34(4):56-8. PubMed ID: 2744382
    [No Abstract]   [Full Text] [Related]  

  • 50. Cyclophosphamide, doxorubicin, prednisone and vindesine combination chemotherapy in melphalan-resistant multiple myeloma.
    Van Dobbenburgh OA; Houwen B; Piersma H; Marrink J; Ockhuizen T; Halie MR; Nieweg HO
    Neth J Med; 1984; 27(2):25-30. PubMed ID: 6709108
    [No Abstract]   [Full Text] [Related]  

  • 51. Oral versus intravenous melphalan and prednisone treatment in multiple myeloma stage II. A randomized study from the Myeloma Group of Central Sweden.
    Osterborg A; Ahre A; Björkholm M; Björeman M; Brenning G; Gahrton G; Grimfors G; Gyllenhammar H; Hast R; Johansson B
    Acta Oncol; 1990; 29(6):727-31. PubMed ID: 2223143
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Myeloma with extramedullary extension coinciding with the normalization of serum paraproteins after treatment].
    Bernat S; Gozalbo T; García-Boyero R; Guinot M
    Sangre (Barc); 1998 Feb; 43(1):96-7. PubMed ID: 9577192
    [No Abstract]   [Full Text] [Related]  

  • 53. Maintenance therapy in multiple myeloma.
    Kumar S
    Clin Adv Hematol Oncol; 2014 Feb; 12(2):133-4. PubMed ID: 24892259
    [No Abstract]   [Full Text] [Related]  

  • 54. Combination therapy of Thalidomide and Peginterferon in patients with progressive multiple myeloma.
    Kasper B; Moehler T; Neben K; Ho AD; Goldschmidt H
    Ann Oncol; 2004 Jan; 15(1):176-7. PubMed ID: 14679142
    [No Abstract]   [Full Text] [Related]  

  • 55. Combination of pamidronate and thalidomide in the therapy of treatment-resistant multiple myeloma.
    Ciepłuch H; Baran W; Hellmann A
    Med Sci Monit; 2002 Apr; 8(4):PI31-6. PubMed ID: 11951079
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Etoposide plus idarubicin and prednisone in refractory or relapsed multiple myeloma. A phase II study.
    Capnist G; Chisesi T
    Haematologica; 1988; 73(5):431-2. PubMed ID: 3143647
    [No Abstract]   [Full Text] [Related]  

  • 57. Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease.
    Ramasamy K; Hazel B; Mahmood S; Corderoy S; Schey S
    Br J Haematol; 2011 Dec; 155(5):632-4. PubMed ID: 21689088
    [No Abstract]   [Full Text] [Related]  

  • 58. [Treatment of multiple myeloma: renal function in relation to its prognosis].
    Akashi M; Ohta M; Kitagawa S; Furukawa Y; Takeda K; Muroi K; Komatsu N; Ikeda K; Ohsaka A; Yoshida M
    Rinsho Ketsueki; 1988 Nov; 29(11):1991-7. PubMed ID: 3236408
    [No Abstract]   [Full Text] [Related]  

  • 59. Failure to achieve early disease response is associated with inferior survival in patients with newly diagnosed multiple myeloma.
    Chee A; Low MS; Vilcassim S; Gregory GP; Gilbertson M; Ratnasingam S; Grigoriadis G; Fedele PL
    Br J Haematol; 2018 Sep; 182(5):739-741. PubMed ID: 28857117
    [No Abstract]   [Full Text] [Related]  

  • 60. A singular case of multiple myeloma and primary biliary cirrhosis strictly associated in pathogenesis and response to alkylating therapy.
    Lazzaro A; Bernuzzi P; Arcari A; Bertè R; Moroni FC; Trabacchi E; Vallisa D; Cavanna L
    Am J Hematol; 2006 Jul; 81(7):557. PubMed ID: 16755555
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.